Skip to main content
Top
Published in: Esophagus 4/2012

01-12-2012 | Original Article

Prevalence and trends of malignant and benign esophageal lesions in Iran between 1997 and 2007

Authors: Shokouh Taghipour-zahir, Fariba Binesh, Naeemeh Sadat Mosavi

Published in: Esophagus | Issue 4/2012

Login to get access

Abstract

Background

Esophageal cancer is one of the most common malignancies with high mortality worldwide. It comprises two major subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Prevalence of each subtype varies substantially in different geographic regions. In Iran and China, for instance, squamous cell carcinoma predominates. Most Iranian studies regarding benign and malignant lesions of the esophagus to date have focused on the northern part of the country, and a knowledge gap exists regarding the prevalence of esophageal lesions in other parts of the country.

Methods

To assess the prevalence and frequency of benign and malignant esophageal lesions, clinical history of patients who underwent upper gastrointestinal endoscopy and biopsy between 1997 and 2007 in Yazd, Iran was reviewed.

Results

Among 294 malignant lesions, squamous cell carcinoma was the most frequent subtype (70.06 %), followed by adenocarcinoma (29.25 %). Of the 387 benign lesions, most frequent diagnoses were reflux esophagitis 215 (55.5 %), esophagus ulcer 91 (23.51 %), and Barrett’s esophagus 73 (18.86 %). During the 11-year study period, incidence of adenocarcinoma gradually increased over time. On the other hand, squamous cell carcinoma incidence and total incidence of esophageal malignancies did not show a significant trend over time.

Conclusions

Squamous cell carcinoma remains the most common subtype of esophagus malignancies in Yazd, Iran, although an increasing trend towards adenocarcinoma is also evident.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
go back to reference Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
4.
go back to reference Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRef Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRef
5.
go back to reference Tran GD, Sun X-D, Abnet CC, Fan J-H, Dawsey SM, Dong Z-W, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.PubMedCrossRef Tran GD, Sun X-D, Abnet CC, Fan J-H, Dawsey SM, Dong Z-W, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.PubMedCrossRef
6.
go back to reference Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.PubMedCrossRef Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.PubMedCrossRef
7.
go back to reference Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.PubMedCrossRef Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.PubMedCrossRef
8.
go back to reference Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.PubMedCrossRef Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.PubMedCrossRef
9.
go back to reference Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–13.PubMedCrossRef Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–13.PubMedCrossRef
10.
go back to reference Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett’s esophagus. An overrated risk? Gastroenterology. 1984;87:927–33.PubMed Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett’s esophagus. An overrated risk? Gastroenterology. 1984;87:927–33.PubMed
11.
go back to reference Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.PubMedCrossRef Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.PubMedCrossRef
12.
go back to reference Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al. Barrett’s esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212–6.PubMedCrossRef Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al. Barrett’s esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212–6.PubMedCrossRef
13.
go back to reference Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–97.PubMedCrossRef Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–97.PubMedCrossRef
14.
go back to reference Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Malekzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran—a review. Eur J Cancer. 2009;45:3156–65.PubMedCrossRef Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Malekzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran—a review. Eur J Cancer. 2009;45:3156–65.PubMedCrossRef
15.
go back to reference Taghavi N, Nasrollahzadeh D, Merat S, Yazdanbod A, Hormazdi M, Sotoudeh M, et al. Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases. World J Gastroenterol. 2007;13:5367–70.PubMed Taghavi N, Nasrollahzadeh D, Merat S, Yazdanbod A, Hormazdi M, Sotoudeh M, et al. Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases. World J Gastroenterol. 2007;13:5367–70.PubMed
16.
go back to reference Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev. 2006;7:375–80.PubMed Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev. 2006;7:375–80.PubMed
17.
go back to reference Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107:113–8.PubMedCrossRef Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107:113–8.PubMedCrossRef
18.
go back to reference Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004;57:37–42.PubMedCrossRef Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004;57:37–42.PubMedCrossRef
19.
go back to reference Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–34.PubMed Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–34.PubMed
20.
go back to reference Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004;126:903–13.PubMedCrossRef Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004;126:903–13.PubMedCrossRef
21.
go back to reference Wallerstein C. Costa Rica tackles high rates of stomach cancer. BMJ. 2001;323:1270.CrossRef Wallerstein C. Costa Rica tackles high rates of stomach cancer. BMJ. 2001;323:1270.CrossRef
22.
go back to reference Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer. 1973;28:197–214.PubMedCrossRef Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer. 1973;28:197–214.PubMedCrossRef
23.
go back to reference Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10:70–82.PubMed Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10:70–82.PubMed
24.
go back to reference Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer. 2004;90:1402–6.PubMedCrossRef Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer. 2004;90:1402–6.PubMedCrossRef
25.
go back to reference Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98:1857–63.PubMedCrossRef Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98:1857–63.PubMedCrossRef
26.
go back to reference Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case–control study. BMJ. 2009;338:b929.PubMedCrossRef Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case–control study. BMJ. 2009;338:b929.PubMedCrossRef
27.
go back to reference Nasseri-Moghaddam S, Malekzadeh R, Sotoudeh M, Tavangar M, Azimi K, Sohrabpour A–A, et al. Lower esophagus in dyspeptic Iranian patients: a prospective study. J Gastroenterol Hepatol. 2003;18:315–21.PubMedCrossRef Nasseri-Moghaddam S, Malekzadeh R, Sotoudeh M, Tavangar M, Azimi K, Sohrabpour A–A, et al. Lower esophagus in dyspeptic Iranian patients: a prospective study. J Gastroenterol Hepatol. 2003;18:315–21.PubMedCrossRef
28.
go back to reference Polednak AP. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98–100.PubMedCrossRef Polednak AP. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98–100.PubMedCrossRef
29.
go back to reference Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–53.PubMedCrossRef Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–53.PubMedCrossRef
30.
go back to reference Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012.
31.
go back to reference Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645–54.PubMedCrossRef Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645–54.PubMedCrossRef
32.
go back to reference Lu C-L, Lang H-C, Luo J-C, Liu C-C, Lin H-C, Chang F-Y, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269–74.PubMedCrossRef Lu C-L, Lang H-C, Luo J-C, Liu C-C, Lin H-C, Chang F-Y, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269–74.PubMedCrossRef
33.
go back to reference Melhado RE, Alderson D, Tucker O. The changing face of esophageal cancer. Cancers. 2010;2:1379–404.CrossRef Melhado RE, Alderson D, Tucker O. The changing face of esophageal cancer. Cancers. 2010;2:1379–404.CrossRef
34.
go back to reference Hongo M. Review article: Barrett’s oesophagus and carcinoma in Japan. Aliment Pharmacol Ther. 2004;20:50–4.PubMedCrossRef Hongo M. Review article: Barrett’s oesophagus and carcinoma in Japan. Aliment Pharmacol Ther. 2004;20:50–4.PubMedCrossRef
35.
go back to reference Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. In: Schneider PM, editor. Adenocarcinoma of the esophagogastric junction. Springer, Berlin; 2010. p. 1–17. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. In: Schneider PM, editor. Adenocarcinoma of the esophagogastric junction. Springer, Berlin; 2010. p. 1–17.
36.
go back to reference Foroutan M, Norouzi A, Molaei M, Mirbagheri S, Irvani S, Sadeghi A, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Dig Dis Sci. 2010;55:28–31.PubMedCrossRef Foroutan M, Norouzi A, Molaei M, Mirbagheri S, Irvani S, Sadeghi A, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Dig Dis Sci. 2010;55:28–31.PubMedCrossRef
37.
go back to reference Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562–72.PubMedCrossRef Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562–72.PubMedCrossRef
38.
go back to reference McFadden DW, Rudnicki M, Talamini MA. Primary small cell carcinoma of the esophagus. Ann Thorac Surg. 1989;47:477–80.PubMedCrossRef McFadden DW, Rudnicki M, Talamini MA. Primary small cell carcinoma of the esophagus. Ann Thorac Surg. 1989;47:477–80.PubMedCrossRef
39.
go back to reference Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–9.PubMedCrossRef Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–9.PubMedCrossRef
40.
go back to reference Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer. 1988;61:612–7.PubMedCrossRef Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer. 1988;61:612–7.PubMedCrossRef
Metadata
Title
Prevalence and trends of malignant and benign esophageal lesions in Iran between 1997 and 2007
Authors
Shokouh Taghipour-zahir
Fariba Binesh
Naeemeh Sadat Mosavi
Publication date
01-12-2012
Publisher
Springer Japan
Published in
Esophagus / Issue 4/2012
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-012-0343-7

Other articles of this Issue 4/2012

Esophagus 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.